All In Biotech

Investigational drug · Phase 3

Tabirafusp tedromer

Also called: KSI-501

Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Diabetic Macular Edema (DME), Wet Age-related Macular Degeneration.

Phase 3

Last checked: Nov 19, 2026Latest source record: Nov 5, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

2

2 still active

All registered trials

2

Any phase or sponsor naming "Tabirafusp tedromer"

First trial start

2024

Aug 23, 2024

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "Tabirafusp tedromer", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Diabetic Macular Edema (DME)
  • Wet Age-related Macular Degeneration

Approved drugs for the same conditions: Wet macular degeneration · Diabetic macular edema · Cardiovascular and metabolic · Ophthalmology

Largest trials

Live from ClinicalTrials.gov: studies naming "Tabirafusp tedromer" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 2 on PubMed

Also in development for Diabetic Macular Edema (DME)

  • 4D-1503E10 vg, eyePhase 35 trials

    4D Molecular Therapeutics · Neovascular Age-Related Macular Degeneration (nAMD), Diabetic Macular Edema (DME), Neovascular (Wet) Age-Related Macular Degeneration

  • TiespectusEYE201, MK-8748Phase 35 trials

    EyeBiotech Ltd. · Macular Degeneration, Age-Related Macular Degeneration, Choroidal Neovascularization

  • EYP-1901Phase 34 trials

    EyePoint Pharmaceuticals, Inc. · Diabetic Macular Edema, DME, Diabetic Macular Edema (DME)

  • OLN324Phase 34 trials

    Ollin Biosciences, Inc. · Diabetic Macular Edema (DME), Wet Age Related Macular Degeneration, Wet Age-related Macular Degeneration

  • RemigromigEYE103, RestoretPhase 33 trials

    EyeBiotech Ltd. · Diabetic Macular Edema (DME), Neovascular Age-Related Macular Degeneration (NVAMD), Branch Retinal Vein Occlusion (BRVO)

  • BAT5906Phase 32 trials

    Bio-Thera Solutions · Diabetic Macular Edema (DME), Neovascular (Wet) Age-related Macular Degeneration

  • RC28-EPhase 31 trial

    RemeGen Co., Ltd. · Diabetic Macular Edema (DME), wAMD

  • BGE-102Phase 22 trials

    BioAge Labs, Inc. · Diabetic Macular Edema (DME), Obesity and Cardiovascular Risk

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.